

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

This announcement appears for information purposes only and does not constitute or form part of any prospectus, invitation or offer to acquire, purchase or subscribe for any securities nor shall it or any part of it form the basis of or be relied upon in connection with any contract or commitment whatsoever. In particular, this announcement does not constitute and is not an offer to sell or a solicitation of any offer to buy securities in Hong Kong or elsewhere.



Genscript Biotech Corporation

(Incorporated in the Cayman Islands with limited liability)
(Stock code: 1548)

INSIDE INFORMATION PROPOSED SPIN-OFF AND SEPARATE LISTING OF PROBIO TECHNOLOGY LIMITED

This announcement is made by the board of directors (the “**Board**”) of Genscript Biotech Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), and Practice Note 15 (“**PN15**”) of the Listing Rules.

THE PROPOSED SPIN-OFF

The Board hereby announces that the Company proposes to spin-off and separately list the shares of Probio Technology Limited (“**ProBio**”), an indirect non-wholly-owned subsidiary of the Company which operates the Group’s Biologics and Advanced Therapy Contract Research, Development, and Manufacturing Organization services, on the Main Board of the Stock Exchange (the “**Proposed Spin-off**”).

In connection with the Proposed Spin-off, the Company submitted an application to the Stock Exchange in compliance with PN15. On 14 August 2026, the Listing Committee confirmed that the Company may proceed with the Proposed Spin-off.

Details of the Proposed Spin-off have yet to be finalized. Upon completion of the Proposed Spin-off, the Company will continue to hold a controlling interest in ProBio, which will remain as a subsidiary of the Company, and its financial results will continue to be consolidated into the financial statements of the Group.

GENERAL

Pursuant to the requirements under PN15, the Company is required to have due regard to the interests of its existing shareholders by providing them with an assured entitlement to the shares to be issued by ProBio (the “**Assured Entitlement**”) by way of a preferential application if the Proposed Spin-off proceeds, subject to certain conditions, including the approval of the Stock Exchange and other regulatory authorities for the Proposed Spin-off. The terms of such Assured Entitlement have not been finalized but in any event all the qualifying shareholders of the Company will be treated equally. The Company will make further announcements in this regard as and when appropriate pursuant to the Listing Rules.

The Proposed Spin-off, if materialized, will constitute a deemed disposal of the interest in a subsidiary of the Company under Rule 14.29 of the Listing Rules. The Company will comply with the applicable requirements of Chapter 14 of the Listing Rules and the requirements under PN15 as and when appropriate.

As the Proposed Spin-off is subject to, among other things, final approval by the Listing Committee, market conditions, and other considerations, the Proposed Spin-off may or may not materialize. Shareholders and other investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Genscript Biotech Corporation
Robin Meng
Chairman and Executive Director

Hong Kong, 4 September 2026

As at the date of this announcement, the executive Directors are Mr. Robin Meng, Dr. Frank Zhang, Dr. Li Zhu and Ms. Sally Wang; and the independent non-executive Directors are Dr. Alphonse Galdes, Mr. Andy Cheung, Mr. Ethan Pan, Dr. John Quelch, Dr. Ross Grossman and Dr. Victor Shi.